Many patients with severe infections like sepsis or COVID-19 have dangerously low levels of lymphocytes, a type of white blood cell. This shortage weakens the immune system and makes fighting the virus harder. A recent review looked at four studies involving patients with infection-associated lymphopenia to see if recombinant human interleukin-7 could help. This medicine is designed to boost those specific cell counts.
The data shows clear success in raising cell numbers. In sepsis patients, lymphocyte counts increased significantly at three and four weeks. In combined data, counts also rose at these time points. For COVID-19 patients, counts did not significantly increase at thirty days. The drug also reduced the risk of secondary infections in the combined group of patients.
However, the most important news is about survival and safety. The drug failed to reduce mortality in sepsis patients. It also did not reduce death rates in COVID-19 patients. While secondary infections were reduced in the combined analysis, the review notes that confounding factors related to the pandemic context must be taken into account. No serious adverse events were reported during the studies.
The bottom line is that this treatment effectively fixes the low cell count problem but does not improve overall prognosis or save lives. Patients and doctors need to understand that fixing the number does not always mean fixing the outcome.
